Karyopharm Therapeutics, Inc. (KPTI)
1.79
+0.02
(+1.13%)
USD |
NASDAQ |
Sep 04, 16:00
1.79
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics SG&A Expense (TTM) : 101.98M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 101.98M |
| March 31, 2026 | 104.54M |
| December 31, 2025 | 105.21M |
| September 30, 2025 | 109.63M |
| June 30, 2025 | 110.65M |
| March 31, 2025 | 113.24M |
| December 31, 2024 | 115.44M |
| September 30, 2024 | 118.94M |
| June 30, 2024 | 122.11M |
| March 31, 2024 | 125.52M |
| December 31, 2023 | 131.88M |
| September 30, 2023 | 135.84M |
| June 30, 2023 | 139.68M |
| March 31, 2023 | 142.54M |
| December 31, 2022 | 145.40M |
| September 30, 2022 | 145.31M |
| June 30, 2022 | 145.77M |
| March 31, 2022 | 144.96M |
| December 31, 2021 | 143.85M |
| September 30, 2021 | 143.21M |
| June 30, 2021 | 139.08M |
| March 31, 2021 | 133.39M |
| December 31, 2020 | 126.42M |
| September 30, 2020 | 120.88M |
| June 30, 2020 | 115.18M |
| Date | Value |
|---|---|
| March 31, 2020 | 109.00M |
| December 31, 2019 | 105.42M |
| September 30, 2019 | 95.80M |
| June 30, 2019 | 83.50M |
| March 31, 2019 | 68.33M |
| December 31, 2018 | 48.85M |
| September 30, 2018 | 36.23M |
| June 30, 2018 | 29.08M |
| March 31, 2018 | 26.23M |
| December 31, 2017 | 24.87M |
| September 30, 2017 | 25.26M |
| June 30, 2017 | 25.34M |
| March 31, 2017 | 24.66M |
| December 31, 2016 | 23.95M |
| September 30, 2016 | 22.67M |
| June 30, 2016 | 21.54M |
| March 31, 2016 | 21.74M |
| December 31, 2015 | 21.58M |
| September 30, 2015 | 22.24M |
| June 30, 2015 | 21.29M |
| March 31, 2015 | 18.44M |
| December 31, 2014 | 15.95M |
| September 30, 2014 | 12.51M |
| June 30, 2014 | 10.28M |
| March 31, 2014 | 6.967M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Madrigal Pharmaceuticals, Inc. | 1.007B |
| Relay Therapeutics, Inc. | 50.06M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |